OARS funding Neuroscience

The Rita Allen Foundation Scholars program funds basic biomedical research in the fields of cancer, immunology, and neuroscience, as well as pain through the Rita Allen Foundation Award in Pain. Rita Allen Foundation Scholars are distinguished by their bold approaches to basic scientific questions that address problems of global concern, as well as their potential for learning, leadership and collaboration.

The Laura Bassi Scholarship was established by Editing Press in 2018 with the aim of providing editorial assistance to postgraduates and junior academics whose research focuses on neglected topics of study, broadly construed, within their disciplines.

The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Specifically, the Prevention Beyond the Pipeline RFP supports: * Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) * Comparative Effectiveness Research: Methods may include randomized trials or epidemiology. * Studies of Cognitive Decline and Cognitive Reserve: Methods may include epidemiology or clinical trials. Current target areas of interest include: - Epigenetics - Inflammation - Mitochondria & metabolic function - Neuroprotection - Proteostasis - Synaptic activity and neurotransmitters - Vascular function - Other aging targets (e.g. senescent cells) - Other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to age-related cognitive decline or dementia risk   

The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. Specifically, this RFP focuses on: - developing novel PET ligands for clinical use - supporting novel CSF biomarkers - validating established MRI approaches in larger cohorts Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include: - Neuronal loss - Vascular injury and blood-brain barrier integrity - Mitochondria and metabolic function - Protein misfolding/proteostasis - Oxidative stress - White matter changes - Other novel targets supported by compelling biological rationale and connection to disease The ADDF has limited interest in CSF measures of amyloid and tau.

The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.

Conducting exceptional clinical research requires close collaboration between academic and industry professionals. Our year-long Clinical Research Fellowships in Oncology, Neurology, Immunology, Ophthalmology, Pulmonary Medicine and other specialty areas give fellows the crucial experience they need to transform knowledge into practice, working directly with top institutions and physicians to strengthen our commitment to developing innovative new medicines.

The Children's Heart Foundation's 2020 Call for Research Proposals is now open! The Children's Heart Foundation funds life-saving, life-changing congenital heart defect (CHD) research in clinical cardiology, translational research, population science, and advancement, prevention, detection of surgical and interventional techniques including, but not limited to the following areas:  Genetics Biochemistry Pharmacology Devices and procedural research (cardiac catheterization and surgery) Neurodevelopmental and functional outcomes Quality and policy regarding delivery of care, coverage, and access Maternal environment and modifiable disease impact on fetuses with CHD Fetal diagnosis and intervention Long-term care of adults with CHDs Technological development and advancements

The Children's Heart Foundation's 2020 Call for Research Proposals is now open! The Children's Heart Foundation funds life-saving, life-changing congenital heart defect (CHD) research in clinical cardiology, translational research, population science, and advancement, prevention, detection of surgical and interventional techniques including, but not limited to the following areas:  Genetics Biochemistry Pharmacology Devices and procedural research (cardiac catheterization and surgery) Neurodevelopmental and functional outcomes Quality and policy regarding delivery of care, coverage, and access Maternal environment and modifiable disease impact on fetuses with CHD Fetal diagnosis and intervention Long-term care of adults with CHDs Technological development and advancements

This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Reissue of RFA-NS-18-032. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program. Other anticipated benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, thereby allowing investigators to spend more time conducting and overseeing research; and More time for PDs/PIsto mentor junior scientists. Eligibility to apply through this FOA is limited to investigators who currently have at least one active NINDS R01 or R01 equivalent grant (defined here as R00, R01, R37, R56, DP1 or DP2 awards), and who have had an active R01 equivalent grant from NINDS in each of the past 5 years, with no more than one of those years in a no cost extension.

To that end, the foundation is inviting applications for innovative research with the potential to increase the basic understanding of these uncommon tumors and lead to the development of more effective therapies. Grants ranging between $100,000 to $1.2 million will be awarded in support of projects over one to four years in the areas of basic, translational, or clinical neuroendocrine cancer research. Four different grants will be awarded: Accelerator Award - Grants of up to $1.2 million over four years will be awarded to projects that bring together investigators from diverse scientific disciplines. Investigator Awards - Grants of up to $300,000 over two years will be awarded to investigators and teams with the tools to study neuroendocrine cancers in innovative and transformative ways. Pilot Awards - Grants of up to $100,000 over one year will be awarded for pilot studies. Mentored Awards - Grants of up to $120,000 over two years will be awarded to encourage early-career investigators to pursue neuroendocrine tumor research and make a commitment to the field.

What: Awards a young scientist for the most outstanding neurobiological research based on methods of molecular and cell biology conducted by them during the past three years Who should apply: Neurobiologists who are under 35 and received their advanced degree within the past 10 years

The NETP Program Synergistic Idea Award supports new ideas that represent synergistic approaches to neurotoxin exposure and treatment-related Parkinson's disease research involving two to four Principal Investigators (PIs) at the Assistant Professor (or equivalent) level or above. These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in neurotoxin exposure and treatment-related Parkinson's research. This award is designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields. The NETP Program seeks applications from investigators working in a wide spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research.

The NETP Program EIRA supports neurotoxin exposure and treatment-related Parkinson's disease research opportunities for investigators in the early stages of their careers, under the guidance of a designated Mentor(s). The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of Parkinson's disease research; however, the PI is not required to have previous Parkinson's disease research experience. Applications must include at least one Mentor, appropriate to the proposed research project, who has experience in Parkinson's disease research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a neurotoxin exposure and treatment-related Parkinson's disease researcher.

The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

The NETP Program IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to neurotoxin exposure and treatment-related Parkinson's research. This award mechanism supports the full spectrum of research from basic science through clinical research.

This funding opportunity announcement aims to support research that employs innovative scalable technologies to inventory, register and profile the cellular ensembles and/or cell-types that produce and/or respond to opioids. Emphasis is on approaches that enable high-throughput single-cell resolution mapping, anatomical characterization and/or molecular profiling of cells identified as primary sources of, or pharmacological targets of, opioids in the brain and/or whose changes in activity associate with opioid-related behaviors in rodents.

Under the RFP, grants of up to $100,000 will be awarded in support of research projects with the potential to advance medical knowledge of acromegaly disease, including its complications and treatment with pegvisomant. Projects submitted may include morbidity and mortality in patients with Acromegaly/GH Excess; laboratory investigations on effects of pegvisomant; clinical outcomes, quality of life, and patient-reported outcomes associated with monotherapy or combination therapy, including pegvisomant; and pharmacoeconomics such as but not limited to resource utilization, patient-reported outcomes, and treatment patterns.

Repeated exposure to drugs of abuse can cause changes in neuronal structure and function that contribute to and sustain drug use. Research has largely focused on the interactions of drugs with specific neuronal targets, and on the consequences of drug exposure on neuronal function, excitability, neuroplasticity, and neurochemistry. However, emerging evidence shows that neuroimmune factors, released from both glia or neurons, can modulate neuronal structure and function, either by affecting neuron-glia interactions or through direct effects on neurons. Yet the role of neuroimmune signaling in the modulation of neuronal function as it affects the expression of substance use behaviors is poorly understood. Research has shown that drugs of abuse, including methamphetamine, morphine, cocaine and nicotine, can elicit neuroinflammatory responses. Stress, an important contributor to relapse, can also elicit neuroimmune responses. Consequently, neuroimmune signaling may be integral to mechanisms underlying drug misuse, addiction, and other consequences of repeated drug use. Further, because the molecular targets and receptors for abused substances differ, the complement of neuroimmune factors affected by exposure to a particular drug may be drug-specific. Research to identify the commonalities between specific drugs of abuse, the neuroimmune factors released by drug use, and the neuroanatomical specificity of the responses is needed. It is expected that the contributing actions of neuroimmune signaling to addictive behaviors are most likely due not to obvious brain damage and overt pathology, but to the consequences of such signaling in altering specific molecular and cellular processes within glia, neurons, and neural circuits.